Scandinavian Prospective Randomised Outcome Study of Hemofiltration and Hemodialysis in Incident Dialysis Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN83264534

Enrollment

Registered

2006-04-27

Start date

2000-05-15

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease patients starting dialysis treatment Nutritional, Metabolic, Endocrine Renal disease

Interventions

Two different modes of dialysis, conventional hemodialysis (HD) versus hemofiltration (HF)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male and female patients with chronic renal failure 2. Age =20 and =80 years 3. Dialysis treatment 1 year

Exclusion criteria

Exclusion criteria: 1. History of myocardial infarction within 3 months 2. Unstable angina 3. Severe cardiac valvular disease 4. Severe cardiac failure (New York Heart Association [NYHA] III-IV) 5. Disseminated malignancy 6. Expected time in hemodialysis 3 months 10. Body weight =100 kg

Design outcomes

Primary

Measure	Time frame
The objective of this study is to compare the effect of treatment with pre-dilution HF and HD, respectively, on left ventricular mass index (LVMI) during 1 to a maximum of 3 years follow up	—

Secondary

Measure	Time frame
To compare the effect of HF and HD with respect to: 1. Mortality (all causes) 2. Hospitalisation (number of occasions, total number of days in hospital) 3. Blood pressure (antihypertensive drug index) 4. Dose of recombinant human erythropoietin (rHuEPO) needed to keep hemoglobin at target level 5. Infections (antibiotic drug index) 6. Serum lipids 7. Patients? subjective evaluation of intra- and inter-dialytic symptoms 8. Residual renal function 9. Cost effectiveness	—

Measure

Time frame

To compare the effect of HF and HD with respect to: 1. Mortality (all causes) 2. Hospitalisation (number of occasions, total number of days in hospital) 3. Blood pressure (antihypertensive drug index) 4. Dose of recombinant human erythropoietin (rHuEPO) needed to keep hemoglobin at target level 5. Infections (antibiotic drug index) 6. Serum lipids 7. Patients? subjective evaluation of intra- and inter-dialytic symptoms 8. Residual renal function 9. Cost effectiveness

—

Countries

Denmark, Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026